clear cell sarcoma
clear cell sarcoma
Explore linked clinical trials. Standard reference: MONDO:000292611 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Eye Diseases, Hereditary, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Malignant Peripheral Nerve Sheath Tumors, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, carcinoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, eye disorder, fibrosarcoma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, retinal cancer, retinal disorder, retinoblastoma, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-10-08 | NCT03618381 | |
| A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, clear cell sarcoma, connective tissue neoplasm, neoplasm, sarcoma | Recruiting | Phase 2 | 2026-10-02 | NCT06942442 | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Carcinoma, Medullary, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Liver Neoplasms, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, alveolar soft part sarcoma, benign urinary system neoplasm, carcinoma, central nervous system cancer, clear cell sarcoma, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, hepatoblastoma, hepatocellular carcinoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, liver disorder, malignant endocrine neoplasm, medullary thyroid gland carcinoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, osteosarcoma, primitive neuroectodermal tumor, renal cell carcinoma, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-08-28 | NCT02867592 | |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Metastatic Dermatofibrosarcoma Protuberans, Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, Urogenital Abnormalities, Urogenital Diseases, Well Differentiated Liposarcoma, angiosarcoma, clear cell sarcoma, connective tissue neoplasm, dermatofibrosarcoma protuberans, disorder of sexual differentiation, endocrine system disorder, epithelioid hemangioendothelioma, extraskeletal myxoid chondrosarcoma, fibrosarcoma, glomus tumor, gonadal disorder, granular cell cancer, granular cell tumor, hemangioendothelioma, hemangioma, histiocytoma, Angiomatoid fibrous, inflammatory leiomyosarcoma, intimal sarcoma, leiomyosarcoma, liposarcoma, low grade fibromyxoid sarcoma, malignant myoepithelioma, malignant perineurioma, mixed neoplasm, myoepithelial tumor, myomatous neoplasm, myxofibrosarcoma, myxoid liposarcoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, sarcoma, synovial sarcoma, undifferentiated (embryonal) sarcoma, vascular cancer | Recruiting | Phase 1 / Phase 2 | 2026-08-03 | NCT06239272 | |
| Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, clear cell sarcoma, connective tissue neoplasm, dedifferentiated chondrosarcoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2026-07-31 | NCT04458922 | |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Peripheral Nerve Sheath Tumors, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, alveolar soft part sarcoma, benign urinary system neoplasm, chordoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myoepithelial tumor, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT06625190 | |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | Adrenocortical Cancer, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Malignant Peripheral Nerve Sheath Tumors, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, benign urinary system neoplasm, carcinoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, endocrine system disorder, epithelial neoplasm, fibrosarcoma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, malignant endocrine neoplasm, malignant germ cell tumor, melanocytic neoplasm, melanoma, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin disorder, skin neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-05-19 | NCT04897321 | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Eye Diseases, Hereditary, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Malignant Peripheral Nerve Sheath Tumors, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, benign urinary system neoplasm, carcinoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, eye disorder, fibrosarcoma, hepatoblastoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, melanocytic neoplasm, melanoma, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroendocrine neoplasm, neuroepithelial neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, ocular cancer, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, retinal cancer, retinal disorder, retinoblastoma, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin disorder, skin neoplasm, synovial sarcoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-04-28 | NCT04483778 | |
| Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelioid hemangioendothelioma, hemangioendothelioma, hemangioma, low grade fibromyxoid sarcoma, myomatous neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, sarcoma, vascular cancer | Recruiting | Not applicable | 2026-02-10 | NCT03967834 | |
| Vebreltinib for Advanced or Metastatic CCS | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, clear cell sarcoma, connective tissue neoplasm, neoplasm, sarcoma | Recruiting | Phase 2 | 2025-09-30 | NCT07153887 | |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | Metastatic Dermatofibrosarcoma Protuberans, Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, adult pleomorphic rhabdomyosarcoma, alveolar soft part sarcoma, angiosarcoma, clear cell sarcoma, connective tissue neoplasm, dermatofibrosarcoma protuberans, extraskeletal Ewing sarcoma, extraskeletal myxoid chondrosarcoma, fibrosarcoma, histiocytoma, leiomyosarcoma, liposarcoma, myomatous neoplasm, myxofibrosarcoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, round cell sarcoma with EWSR1-non-ETS fusion, sarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, vascular cancer | Not yet recruiting | Not applicable | 2024-07-30 | NCT06526897 |